Decoquinate

Decoquinate is an orally active, selective inhibitor of the mitochondrial bc1 complex, targeting Eimeria spp. sporozoites and first generation schizonts, and Plasmodium spp. Decoquinate inhibits electron transfer by competitively binding to the mitochondrial cytochrome b system, blocking the parasite's energy metabolism, thereby inhibiting its development and reproduction. Decoquinate has significant anticoccidial activity, preventing intestinal damage and improving host growth performance, and also has inhibitory effects on the liver and blood stages of Plasmodium. Decoquinate is mainly used in veterinary research to prevent and treat coccidiosis in ruminants and poultry[1][2][3].

Product Specifications

CAS Number

[18507-89-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Parasite

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Decoquinate.html

Purity

99.26

Solubility

DMSO : < 1 mg/mL|H2O : < 0.1 mg/mL

Smiles

O=C(C1=C(O)C2=CC(OCCCCCCCCCC)=C(OCC)C=C2N=C1)OCC

Molecular Formula

C24H35NO5

Molecular Weight

417.54

Precautions

H302, H315, H319, H335

References & Citations

[1]Taylor MA, et, al. The history of decoquinate in the control of coccidial infections in ruminants. J Vet Pharmacol Ther. 2012 Oct;35 (5) :417-27.|[2]Wang H, et al. Nanoparticle formulations of decoquinate increase antimalarial efficacy against liver stage Plasmodium infections in mice. Nanomedicine. 2014 Jan;10 (1) :57-65.|[3]Beteck RM, et al. Straightforward conversion of decoquinate into inexpensive tractable new derivatives with significant antimalarial activities. Bioorg Med Chem Lett. 2016 Jul 1;26 (13) :3006-3009.